Fermer le menu



MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation Aiming to Improve Overall Survival in Patients Undergoing Hematopoietic Stem Cell transplantation


  • MaaT033 (capsule), which is being developed as an adjunctive and maintenance therapy to improve overall survival in allo-HSCT, has received orphan drug designation (ODD) status from the European Medicines Agency (EMA).
  • ODD is reserved for medicines treating rare, life-threatening, or chronically debilitating diseases. The status offers key benefits including market exclusivity, clinical protocol assistance, waivers or reductions in regulatory fees.



View press release



Plus d'infos